These emerging medications , Semaglutide , represent a significant advancement in treating metabolic dysfunction and possibly other disorders. They are classified as GLP-1 receptor agonists , meaning https://estellemopp783018.tkzblog.com/41149799/semaglutide-a-deep-dive-into-metabolic-agents